louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06506500: Unilateral Biportal Endoscopy Lumbar Interbody Fusion (ULIF) Versus Posterior Lumbar Interbody Fusion (PLIF) in Management of Single Level Lumbar Degenerative Disease: A Retrospective Study
Official title: Unilateral Biportal Endoscopy Lumbar Interbody Fusion (ULIF) Versus Posterior Lumbar Interbody Fusion (PLIF) in Management of Single Level Lumbar Degenerative Disease: A Retrospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lumbar Degenerative Disease
Lead sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sponsor class: OTHER
First posted: 2024-07-17
Enrollment: 140
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 1. Patients who have been diagnosed with lumbar disc herniation, lumbar spinal stenosis, or lumbar spondylolisthesis.
2. The patient has clear indications for surgical treatment.
3. The patient is undergoing their initial single-segment ULIF or PLIF surgery at our hospital.

Brief summary: The study aimed to compare the clinical efficacy and safety of unilateral biportal endoscopic lumbar interbody fusion (ULIF) with posterior lumbar interbody fusion (PLIF) in the treatment of single-level lumbar degenerative diseases.


Eligibility criteria: Inclusion Criteria:

1. Patients who have been diagnosed with lumbar disc herniation, lumbar spinal stenosis, or lumbar spondylolisthesis based on their medical history, physical signs, and imaging exams such as lumbar anteroposterior and lateral radiographs (including hyperextension and hyperflexion positions), lumbar CT, and lumbar MR. (2) The patient has clear indications for surgical treatment: ① Conservative treatment for more than three months has been ineffective or the symptoms have continued to worsen ② The patient's symptoms are severe and interfere with their daily work and life ③ The patient exhibits signs of cauda equina nerve compression (such as numbness in the perineal area, loss of bowel and bladder control, etc.).

(3) The patient is undergoing their initial single-segment ULIF or PLIF surgery at our hospital.

Exclusion Criteria:

1. Patients with lumbar degenerative diseases involving two or more segments
2. Pathological changes caused by other diseases, such as spinal infections, spinal trauma, spinal tumors, neurological diseases, etc.
3. Patients with lumbar spondylolisthesis exceeding Meyerding Grade II or degenerative scoliosis with a Cobb angle greater than 20 degrees
4. History of previous lumbar surgery
5. History of previous tumor disease.

Primary outcomes:
measure: ODI
timeFrame: before surgery，1-week，1-month，3-month，6-month and 1-year postoperative
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
state: Guangdong
Study officials:
References:
Clinical trial NCT03030300: Remission Rate of Newly Diagnosed Type 2 Diabetes Outpatients Treated With Short-term Intensive Insulin Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Type2 Diabetes
Keywords: type 2 diabetes
remission
short-term intensive insulin therapy
Lead sponsor: Qianfoshan Hospital
Sponsor class: OTHER
First posted: 2017-01-25
Enrollment: 170
Sex: ALL
Minimum age (years): 18
Maximum age (years): 78
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the long-term remission rate of short-term intensive insulin (STII) therapy in newly diagnosed type 2 diabetes outpatients and investigate the predictors contributing to the remission rate.


Eligibility criteria: Inclusion Criteria:

* Newly diagnosed, insulin-naive type 2 diabetes outpatients
* Diabetes duration less than 1 year

Exclusion Criteria:

* Various acute complications
* Hepatic transaminase \>2.5x normal reference value (glutamic-pyruvic transminase\>100U/L, glutamic-oxalacetic transaminase \> 100U/L)
* Abnormal renal functions (serum cretinine\>the normal reference value)
* Cardiac insufficiency (America NYHA caediac function \>3)
* Type 1 diabetes mellitus
* Ongoing hormone therapy
* Women in gestation and lactation
* Patients with other endocrine disorders

Primary outcomes:
measure: prolonged-remission rate
timeFrame: 5 years
measure: partial-remission rate
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Jinan
country: China
facility: Shandong Provincial Hospital
state: Shandong
city: Jinan
country: China
facility: Qianfoshan Hospital
state: Shandong
city: Jinan
country: China
facility: Qilu Hospital
state: Shandong
Study officials:
affiliation: Qianfoshan Hospital
name: Lin Liao, MD
role: STUDY_CHAIR
References:
Clinical trial NCT00553670: Mechanism and Predictor of Side Branch Jailing
Official title: Predictor and Mechanism of a Side Branch Jail After Main Branch Stent Implantation in Bifurcation Lesions
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Bifurcating Coronary Artery Lesions
Main Branch Stent Implantation
Side Branch Jailing
Keywords: coronary artery
bifurcation
stent
intravascular ultrasound
fractional flow reserve
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2007-11-04
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with bifurcating coronary artery lesion in left anterior descending coronary artery

Brief summary: Coronary artery bifurcation lesion is still one of the most challenging lesion subsets in the field of non-surgical treatment for a stenotic coronary artery. When one stent is placed in the main brach, it increases the side branch's stenosis degree. However, its mechanism and incidence are not known. This study will be performed to search for the mechanism and incidence of that phenomenon.


Eligibility criteria: Inclusion Criteria:

1. Elective coronary intervention (including stabilized ACS patients)
2. Bifurcation lesion with TIMI 3 flow
3. Side branch diameter \> 2mm, side branch lesion length \< 10mm by visual estimation

Exclusion Criteria:

1. Left main coronary disease
2. AMI, or Old MI at LAD territory
3. LVEF \< 40%, or other significant valvular or myocardial disease
4. Significant side branch distal lesion
5. Angiographically visible thrombus
6. Heavily calcified lesion
7. Side branch predilatation before main branch stent implantation

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul national university hospital
Study officials:
affiliation: Seoul National University Hospital
name: Bon-Kwon Koo, PhD
role: STUDY_DIRECTOR
References:
citation: Koo BK, Waseda K, Kang HJ, Kim HS, Nam CW, Hur SH, Kim JS, Choi D, Jang Y, Hahn JY, Gwon HC, Yoon MH, Tahk SJ, Chung WY, Cho YS, Choi DJ, Hasegawa T, Kataoka T, Oh SJ, Honda Y, Fitzgerald PJ, Fearon WF. Anatomic and functional evaluation of bifurcation lesions undergoing percutaneous coronary intervention. Circ Cardiovasc Interv. 2010 Apr;3(2):113-9. doi: 10.1161/CIRCINTERVENTIONS.109.887406.
Clinical trial NCT02976870: Hydronephrosis After Anterior Lumbar Interbody Fusion (ALIF)
Official title: Hydronephrosis After Anterior Lumbar Interbody Fusion (ALIF)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hydronephrosis
Keywords: Hydronephrosis
Anterior Lumbar Interbody Fusion
Lead sponsor: Nottingham University Hospitals NHS Trust
Sponsor class: OTHER
First posted: 2016-11-29
Enrollment: 39
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Anterior lumbar spinal surgery involves making an incision through the abdomen of the patient in order to access the spine. During this process, several internal structures are pushed aside in order to gain access. One of these structures is the ureter, whose function is to drain urine from the kidney to the bladder. One potential complication that can arise from this is dilation of the kidney - known as hydronephrosis. The aim of this study is to identify whether hydronephrosis after Anterior Lumbar Interbody Fusion (ALIF) is complication, in order to bring this to the attention of health care professionals when considering this kind of surgery.

Detailed description: A total of 40 patients who have had ALIF surgery will be invited to have an ultrasound scan of their kidney on the side where the operation was performed (where the scar is). Should hydronephrosis of this kidney be detected, the investigators will go on to scan the second kidney. Should hydronephrosis be detected the patient will be given a letter to take to their General Practitioner (GP) advising them to be referred to a Urologist.

Eligibility criteria: Inclusion Criteria:

* Over 18 years of age
* Has the mental capacity to provide informed consent for participation within the study
* Patients who have had anterior lumbar spinal surgery at least 12 months ago and no longer than 5 years ago

Exclusion Criteria:

* Unable to understand written or verbal information regarding the study
* Multiple abdominal surgeries prior to spinal surgery
* Previous renal complication such as renal strictures or hydronephrosis/use of stents
* Pregnancy
* Structural anomalies

Primary outcomes:
measure: Identification of hydronephrosis on ultrasound scan
timeFrame: 12 month
Secondary outcomes:
Other outcomes:
Locations:
city: Nottingham
country: United Kingdom
facility: Queen's Medical Centre
Study officials:
affiliation: The Centre for Spinal Studies and Surgery, Queen's Medical Centre, Nottingham, NG7 2UH.
name: Bronek Boszczyk, PD. Dr.med.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06157970: Sphenopalatine Ganglion Block in Septorhinoplasty
Official title: The Effect of Sphenopalatine Ganglion Block on Intraoperative Remifentanil Consumption and Postoperative Pain in Septorhinoplasty Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pain, Postoperative
Rhinoplasty
Lead sponsor: Istanbul Medeniyet University
Sponsor class: OTHER
First posted: 2023-12-06
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who operated for septorhinoplasty

Brief summary: Septorhinoplasty is a widely performed surgery that aims to correct both functional and aesthetic problems of the nose. Despite its expected clinical benefits, septorhinoplasty surgery causes postoperative pain, which affects the patient's functional recovery and satisfaction. Opioids, Non-steroidal anti-inflammatory drugs (NSAII), acetaminophen and local anesthetics are used in peroperative pain management in septorhinoplasty. Sphenopalatine ganglion block (SPGB), which has been recently described and has different application areas, is a regional analgesia technique that has been investigated for this purpose. Although there are studies on postoperative pain in septorhinoplasty surgeries, there are not enough studies on its effects on intraoperative pain.

This study may have positive effects on appropriate pain management, patient comfort and surgical outcomes as multimodal analgesia management in septorhinoplasty surgeries, and may make significant contributions to evidence-based practices.


Eligibility criteria: Inclusion Criteria:

* Undergoing septorhinoplasty surgery
* Ages between 18-65
* ASA (American Society of Anesthesiologists) score I-II

Exclusion Criteria:

* Unavailable postoperative pain scores and analgesic use in the hospital registry system
* Local anesthetic drug allergy and toxicity
* Advanced organ failure
* Mental retardation

Patients who are pregnant

Primary outcomes:
measure: remifentanil consumption
timeFrame: 2 hours
Secondary outcomes:
measure: Numerical Rating Scale
timeFrame: 15 minute, 30 minute, 1hour, 2 hour, 4 hour, 8 hour,16 hour, 24 hour
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Suheda Akbulut
Study officials:
References:
Clinical trial NCT04291170: Comparison of Upper Extremity and Lower Extremity Function and Quick DASH
Official title: Comparison of Upper Extremity and Lower Extremity Function and Quick DAS
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Hand Injuries
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2020-03-02
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Patient reported outcome measure (PROM) are a method by which to assess outcomes from a patient perspective. The QuickDASH is a commonly used PROM. QDASH was validated against grip strength and ability work, however not against its ability to actually measure what it sets forth to measure (ie: patient's ability to use a hammer, carry a shopping bag, wash a wall, etc). The purpose of this study is to correlate the self-reported QDASH with patients' ability to perform the functions on the QDASH and compare to a control group who completes the task on a lower extremity PROM, KOOS JR.


Eligibility criteria: Inclusion Criteria:

* new patient
* stanford hand surgery clinic patient

Exclusion Criteria:

-

Primary outcomes:
measure: QDASH score
timeFrame: Immediately after completing the taks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Stanford University
name: Robin N Kamal, MD MBA
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06983470: Predictive Utility and Mechanisms of Sacral Evoked Responses in Sacral Neuromodulation
Official title: Predictive Utility and Mechanisms of Sacral Evoked Responses in Sacral Neuromodulation
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Overactive Bladder
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: Medtronic
First posted: 2025-05-21
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Electrical stimulation of the sacral nerve can help with bladder problems and pelvic pain but researchers don't understand exactly how the stimulation helps. The goal of this study is to examine signals evoked during sacral neuromodulation (SNM or electrical stimulation of the sacral nerve) and their relationship to the selection of stimulation parameters that improve pelvic function symptoms. This study uses SNM parameters based on visual-motor responses (VMR) or sacral evoked responses (SER). It is investigating how the parameter selection impacts change in bladder function.

Detailed description: Some surgical procedures will be conducted at the Chealsea Hospital (75 S Main St, Chelsea, MI 48118) and all others will be done at Michigan Medicine facilities.

Eligibility criteria: Inclusion Criteria:

* Determined by the research team to be fully eligible to receive a sacral neuromodulation implant at a sacral nerve as part of their normal clinical care for overactive bladder (OAB).
* Adult (18 or older), capable of providing own informed consent and communicating clearly with research team.
* Capable of speaking, reading, and understanding English, as all study questionnaires are standardized assessments only available in English.

Exclusion Criteria:

* Areflexive or atonic bladder.
* Pregnant or planning to become pregnant. If a woman of child-bearing potential wishes to participate in this study, they will be pre-screened with a test to detect pregnancy.
* Diagnosed neurogenic bladder, sacral nerve damage, lower motor dysfunction, or other conditions that would affect the neural circuits involved in micturition.

Primary outcomes:
measure: Change in bladder function score during SNM using visual-motor responses (VMR)-selected stimulation programs
timeFrame: Baseline through the conclusion of study participation, approximately 3 months
measure: Change in bladder function score during SNM using sacral evoked responses (SER)-selected stimulation programs
timeFrame: Baseline through the conclusion of study participation, approximately 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan
name: Tim Bruns, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02803970: KOrean Borderline Ovarian Tumor (KOBOT) Registry
Official title: Establishing the Registry of Korean Patients With Borderline Ovarian Tumors
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Ovarian Neoplasms
Lead sponsor: Kangbuk Samsung Hospital
Sponsor class: OTHER
First posted: 2016-06-17
Enrollment: 3000
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Korean patients with borderline ovarian tumors (BOTs)

Brief summary: The aim of this study is to collect data on Korean patients with borderline ovarian tumors.

Detailed description: The researchers retrospectively collected data on Korean patients with borderline ovarian tumors (BOTs) diagnosed, treated, and followed between November 1994 and February 2015 at institutions where placed in the Republic of Korea. And the researchers prospectively will collect data on all Korean patients with BOTs at institutions where placed in the Republic of Korea since March, 2015. If patients agree to participate in this KOBOT registry, patient's data (such as age, body mass index, preoperative findings, laboratory findings, radiologic findings, operative findings, pathologic findings, postoperative findings) will be collected in a research database. The research database will be updated, every 6 month, to include data on patient's disease outcome and follow-up care. Although most data will be collected form the medical record, patient may agin be contacted so that researchers can collection some data if it is not in the medical record.

Eligibility criteria: Inclusion Criteria:

* Patients with borderline ovarian tumors (BOTs) diagnosed, treated, and followed between November 1994 and February 2015 at institutions where placed in the Republic of Korea.
* All patients undergoing gynecologic surgery for BOTs at institutions where placed in the Republic of Korea since March, 2015

Exclusion Criteria:

* Patients who did not receive primary treatment or follow-up for at least 6 months at each institution were excluded from analysis

Primary outcomes:
measure: Recurrence-free survival
timeFrame: up to 100 months
Secondary outcomes:
Other outcomes:
Locations:
city: Changwon
country: Korea, Republic of
facility: Samsung Changwon Hospital
city: Seoul
country: Korea, Republic of
facility: Kangbuk Samsung Hospital
city: Seoul
country: Korea, Republic of
facility: CHA Gangnam Medical Center
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
affiliation: Kangbuk Samsung Hospital
name: Taejong Song, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05979675: Acute Myeloid Leukemia Registry
Official title: Acute Myeloid Leukemia Registry - Prospective National Multicentric Observational Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Acute Myeloid Leukemia
Lead sponsor: Turkish Hematology Association
Sponsor class: OTHER
First posted: 2023-08-07
Enrollment: 250
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All AML patients diagnosed after 1 Jan 2020 will be included to this study.

Brief summary: All acute myeloid leukemia (AML) patients diagnosed after 1 Jan 2020 will be included to this study.

Detailed description: This is a non interventional prospective disease registry, 250 prospective patients diagnosed with AML across 20 centers in Turkey.

Participating sites will consist of hematology clinics and routine follow-up procedures will be followed-up.

All patients diagnosed after 1 Jan 2020 as AML will be included and patients will be enrolled during 24 months of period and will be followed-up 36 months. Study will be completed in 60 months.

Eligibility criteria: Inclusion Criteria:

* Diagnosed as AML after 1 Jan 2020
* Patients signed informed consent form

Exclusion Criteria:

* Patients under 18 years old

Primary outcomes:
measure: Overall Survival
timeFrame: 60 months
Secondary outcomes:
Other outcomes:
Locations:
city: Antalya
country: Turkey
facility: Antalya Training and Research Hospital
Study officials:
affiliation: Sentez Cro
name: Ilker Kurkcu
role: STUDY_DIRECTOR
References:
Clinical trial NCT06368375: Clinical and Genetic Findings in Patients With PRPF31-associated Retinitis Pigmentosa
Official title: Clinical and Genetic Findings in Patients With PRPF31-associated Retinitis Pigmentosa
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Retinitis Pigmentosa
Keywords: retinitis pigmentosa
PRPF31
inherited retinal dystrophy
carrier
Lead sponsor: University Hospital Tuebingen
Sponsor class: OTHER
First posted: 2024-04-16
Enrollment: 87
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with genetically confirmed PRPF31-associated inherited retinal dystrophy or asymptomatic carrier of the respective variant(s)

Brief summary: Retrospective chart review study to elucidate the genotype and phenotype of patients with PRPF31-associated retinitis pigmentosa and asymptomatic carriers of the respective variant(s)


Eligibility criteria: Inclusion Criteria:

* genetically confirmed PRPF31-associated inherited retinal dystrophy or asymptomatic carrier of the respective variant(s)

Exclusion Criteria:

* none

Primary outcomes:
measure: Best Corrected Visual Acuity (BCVA)
timeFrame: September 2007 - January 2022
measure: Visual Field (VF)
timeFrame: September 2007 - January 2022
measure: Fundus Photography (FP)
timeFrame: September 2007 - January 2022
measure: Optos
timeFrame: September 2007 - January 2022
measure: Autofluorescence (AF)
timeFrame: September 2007 - January 2022
measure: Optical Coherence Tomography (OCT)
timeFrame: September 2007 - January 2022
measure: Full-Field Electroretinogram (ff-ERG)
timeFrame: September 2007 - January 2022
Secondary outcomes:
Other outcomes:
Locations:
city: Tuebingen
country: Germany
facility: University Hospital Tuebingen
state: Baden-Wuerttemberg
Study officials:
affiliation: Department for Ophthalmology, University of Tuebingen
name: Laura Kuehlewein, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Molecular Genetics Laboratory, Department for Ophthalmology, University of Tuebingen
name: Susanne Kohl, PhD
role: PRINCIPAL_INVESTIGATOR
References: